This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA), a defense agency, to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $4,999,999, is a single-award IDC valid through December 31, 2025, under the SPE2DX program.
The IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the recurring medical supply needs of military healthcare facilities and veterans' medical centers nationwide. Key products covered include specialized medications such as Xolair, Trikafta, Keytruda, Botox, Nucala, and various other prescription drugs and medical supplies across categories like injections, tablets, creams, auto-injectors, and specialty medications. This contract positions DMS Pharmaceutical Group as a crucial supplier in the federal pharmaceutical supply chain, providing direct distribution of prescription drugs and pharmacy services to Department of Defense healthcare sites.
Generated 7/2/25, 10:47 PM